PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) CEO Daniel Cohen tells Proactive the group is starting DMT studies through a new collaboration with the University of Michigan.
Cohen says the Toronto-based pharmaceutical company is teaming up with the university’s Dr Jimo Borjigin to study the potential role of DMT, or N, N-dimethyltryptamine, in normal, diseased and altered states of consciousness in a newly-created animal model.